Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.

ABSTRACT: Anemia is a common complication in chronic kidney disease (CKD), and is associated with a reduced quality of life, and an increased morbidity and mortality. The mechanisms involved in anemia associated to CKD are diverse and complex. They include a decrease in endogenous erythropoietin (EPO) production, absolute and/or functional iron deficiency, and inflammation with increased hepcidin levels, among others. Patients are most commonly managed with oral or intravenous iron supplements and with erythropoiesis stimulating agents (ESA). However, these treatments have associated risks, and sometimes are insufficiently effective. Nonetheless, in the last years, there have been some remarkable advances in the treatment of CKD-related anemia, which have raised great expectations. On the one hand,

SUBMITTER: Portoles J 

PROVIDER: S-EPMC8032930 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature